Table 1.
Demographic and clinical information for TBI patients.
Figure 1.
99mTc Exametazime and 123I Ioflupane SPECT studies in a 61 year old male subject with multiple prior TBIs presenting with headache and memory loss.
Note the markedly decreased CBF primarily in the frontal lobes bilaterally (yellow arrows). However, this same patient had robust DAT binding in the striatum (blue arrows) with no significant abnormalities.
Figure 2.
99mTc Exametazime and 123I Ioflupane SPECT studies in a 58 year old male subject with a history of a single TBI with clinically presenting with problems with memory, sleep, and vertigo and no clear parkinsonian features.
The CBF shows only a mild decrease in the right temporo-parietal region. However, DAT binding is markedly abnormal with preserved uptake primarily in the caudate (R>L) and minimal uptake in the putamen bilaterally.
Table 2.
General evaluation results of the 99mTc Exametazime and 123I Ioflupane SPECT scans (note that several additional regions were evaluated but not listed).